All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 7, 2021
Home » Blogs » BioWorld MedTech Perspectives » The difference between good news and bad news

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The difference between good news and bad news

June 7, 2013
By Mark McCarty
No Comments

Different faces and stories, same questions?
Different faces and stories, same questions?

There’s an old story about a farmer who lost a horse, and the neighbor said “such bad news.” Then the horse came back with a bunch more in tow, and the neighbor said “such good news!” Then the farmer’s son broke his arm breaking one of the new horses and … well you get the idea. Sometimes you can tell the difference, sometimes not.

With that in mind, we examine two stories appearing recently in the pages of Medical Device Daily.

CMS; Trustees report is happy, happy

The Centers for Medicare & Medicaid Services announced recently the Medicare hospital (Part A) trust fund picked up two additional years of solvency, and CMS said “Medicare spending per beneficiary has grown quite slowly over the past few years and is projected to continue growing slowly over the next several years.”

Continue growing slowly over the next several years? Maybe. Or maybe the recession really did impose drag on Medicare spending and the economic recovery will push growth back to 6% per annum.

Mark Pauly of the Wharton School appeared at a recent confab on the Trustees report, and he remarked that hospitals and makers of therapeutics and diagnostics often shelve big plans when Medicare spending slows. Once spending growth resumes, however, all bets are off.

CMS also claimed the Affordable Care Act helped put a lid on Medicare inflation, but Pauly pointed out that many such fixes exert an ephemeral effect, as was the case with managed care.

I’m not trying to unload on CMS here – it is their job to make the government’s case after all – but I doubt anyone who’s familiar with the territory broke out the bubbly in response to the report, which one could say was bad news for makers of champagne.

Warning letter to Edwards; very big ouch

Edwards Lifesciences announced recently it had received a warning letter from FDA, but it was one of the longest warning letters I’ve ever seen, and I’ve seen a bunch.

Edwards announced a recall during the course of the inspection, but one of the big issues was the firm’s validation of an oven used in the processing of the QuickDraw venous cannulae, which seems to have led to breakage of the cannulae on six occasions.

Are six broken cannulae conspicuous? I can’t say because I have no idea how many were manufactured during the period in question, but worse yet in FDA’s view was that the company changed its story about the cause of the broken cannulae.

I’m not arguing criminal negligence, just that this is interventional cardiology, not a region that’s particularly forgiving of problems, which is why FDA is not particularly forgiving of problems, either.

I’d also point out the agency recently raised the question of Park doctrine in a warning letter to a food producer, and makers of these very high-risk devices would do well to read the tea leaves. Is it a stretch to think government prosecutors would invoke Park doctrine over the results of an inspection of a device maker?

Not if someone died.

The good news here is the Edwards compliance team will visit the plant in Draper, Utah, and tighten some bolts. The bad news is device makers must push the boundaries of design and materials science to reliably manufacture these smaller, more complex devices, and it doesn’t take a big mistake for problems to arise.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 5.
  • Coronavirus vaccine/therapeutics illustration

    Tonix looks to the past for the future of COVID-19 vaccines and testing

    BioWorld MedTech
    Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing